Arbidol treatment with reduced mortality of adult patients with COVID-19 in Wuhan, China: a retrospective cohort study

Qibin Liu^{1*}, Xuemin Fang^{2*}, Lu Tian^{3*}, Naveen Vankadari⁴, Xianxiang Chen⁵, Ke Wang⁶, Dan Li⁷, Xiyong Dai⁸, Feng Xu⁹, Lei Shen¹⁰, Bing Wang¹¹, Li Yao¹², Peng Peng^{13#}

¹ Wuhan Pulmonary Hospital, Wuhan Institute for Tuberculosis Control, No. 28 Baofeng Road, Qiaokou District, Wuhan City, Hubei Province, China; <u>Liuqibin0221@163.com</u>

² Graduate School of Health Innovation, Kanagawa University of Human Services, 2F Bldg.2-A, 3-25-10, Tonomachi Kawasaki-ku, Kawasaki City, Kanagawa 210-0821, Japan, <u>m.fanfg-ft5@kuhs.ac.jp</u>

³ Department of Biomedical Data Science, Stanford University, CA 94305, USA, <u>lutian@stanford.edu</u>

⁴ Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Victoria 3800, Australia. <u>Naveen.vankadari@monash.edu</u>

⁵ Wuhan Pulmonary Hospital, Wuhan Institute for Tuberculosis Control, No. 28 Baofeng Road, Qiaokou District, Wuhan City, Hubei Province, China; <u>2272534937@qq.com</u>

⁶ Department of Pulmonary and Critical Care Medicine, Tongji Hospital, Huazhong University of Science and Technology, 1095 Jiefang Avenue, 430030, Wuhan City, Hubei Province, China, <u>Chinawangke13409@163.com</u>

⁷ Department of Pediatric Surgery, Union Hospital, Huazhong University of Science and Technology, 1277 Jiefang Avenue, 430022, Wuhan City, Hubei Province, China, <u>D201478239@alumni.hust.edu.cn</u>

⁸Wuhan Pulmonary Hospital, Wuhan Institute for Tuberculosis Control, No. 28 Baofeng Road, Qiaokou District, Wuhan City, Hubei Province, China, <u>daixiyong71@126.com</u>

⁹Wuhan Pulmonary Hospital, Wuhan Institute for Tuberculosis Control, No. 28 Baofeng Road, Qiaokou District, Wuhan City, Hubei Province, China, <u>victor fsxq@163.com</u>

¹⁰ Wuhan Pulmonary Hospital, Wuhan Institute for Tuberculosis Control, No. 28 Baofeng Road, Qiaokou District, Wuhan City, Hubei Province, China, <u>shen0811@aliyun.com</u>

¹¹Wuhan Pulmonary Hospital, Wuhan Institute for Tuberculosis Control, No. 28 Baofeng Road, Qiaokou District, Wuhan City, Hubei Province, China, <u>779238021@qq.com</u>

¹² Wuhan Pulmonary Hospital, Wuhan Institute for Tuberculosis Control, No. 28 Baofeng Road, Qiaokou District, Wuhan City, Hubei Province, China, <u>354608920@qq.com</u>

¹³ Wuhan Pulmonary Hospital, Director, Wuhan Institute for Tuberculosis Control, No. 28 Baofeng Road, Qiaokou District, Wuhan City, Hubei Province, China, <u>pengpengwg@126.com</u>

*Authors contributed equally

#Correspondence: pengpengwg@126.com (Tel.:+86-027-83605535)

The worldwide COVID-19 pandemic is increasing exponentially and demands an effective and promising therapy at most emergency.

METHODS

We have assembled a cohort consisting 504 hospitalized COVID-19 patients. Detailed information on patients' characteristics and antiviral medication use during their stay at designated hospitals along with their pre and post treatment results were collected.

The study objective is to evaluate the treatment efficacy of Arbidol, together with the concurrent drugs Oseltamivir and Lopinavir/Ritonavir on mortality and lesion absorption based on chest CT scan.

FINDINGS

The overall mortality rate was 15.67% in the cohort. The older age, lower SpO2 level, larger lesion, early admission date, and the presence of pre-existing conditions were associated with higher mortality. After adjusting for the patients age, sex, pre-existing condition, SpO2, lesion size, admission date, hospital, and concurrent antiviral drug use, Arbidol was found promising and associated with reduced mortality. The OR for Arbidol is 0.183 (95% CI, 0.075 to 0.446; P<0.001). Furthermore, Arbidol is also associated with faster lesion absorption after adjusting for patient's characteristics and concurrent antiviral drug use (P=0.0203).

INTERPRETATION

The broad-spectrum antiviral drug Arbidol was found to be associated with faster

4 Introduction

5 Since the first discovery of novel coronavirus disease 2019 (COVID-19) in Wuhan (China) in

6 December 2019,¹ more than 4.8 million people were infected and over 323,000 have died

7 across the globe as of May 22, 2020,^{2,3} The world-wide rapid spread of the infection with

8 limited therapeutic options is leading to a global health emergency. Meanwhile scientists and

9 researchers are racing with time testing a huge variety of new and existing treatments. As of

- 10 April 8, 2020, there were 388 ongoing studies on COVID-19 that are recorded in the U.S.
- 11 National Library of Medicine of the NIH,⁴ including studies involving plasma, stem cells, and
- 12 antiviral drugs, etc. For example, Liu et al (2020) presented preliminary results for 39 patients
- 13 suggesting a potential benefit of convalescent plasma treatment in reducing mortality.⁵

14 Much attention has been drawn to a few promising candidates, namely Remdesivir,

- 15 Lopinavir/Ritonavir, Hydroxychloroquine, Favipiravir and Umifenovir (Arbidol), however
- 16 most completed studies so far had negative results. Mehra et al (2020) reported a
- 17 multinational registry analysis of 96,032 patients and showed the use of Hydroxychloroquine
- 18 or Chloroquine was associated with decreased in-hospital survival and increased ventricular

19 arrhythmias;⁶ Geleris et al (2020) also reported the result of an observational study of 1446

- 20 patients showing Hydroxychloroquine was not associated with significant benefit on a
- 21 composite endpoint of intubation or death;⁷ Cao et al (2020) reported that no benefit was
- 22 observed with Lopinavir/Ritonavir treatment beyond standard care in a randomized,
- 23 controlled, open-label trial with 199 patients.⁸ Chen et al (2020) reported a randomized
- 24 clinical trial of 240 patients comparing Favipiravir with Arbidol, and found that Favipiravir
- did not significantly improve the clinical recovery rate at Day 7 as compared to Arbidol.⁹
- 26 Remdesivir has been regarded as one of the most promising drug candidates, with a total of
- 27 three trial results becoming available so far.¹⁰⁻¹² It was found to be superior to placebo in
- 28 shortening the time to recovery, but its effect on the mortality was not statistically

29 significant.¹¹ We are still nowhere close to finding the best cure.

- 30 In the search for effective COVID-19 therapies, most researchers are targeting ACE2 and
- 31 RdRp, but recent findings also suggest CD26 (DPP4) as another possible target.^{13,14} Viral
- 32 entry is mediated via several pathways and it may not solely depend on the ACE2 which
- 33 warrants testing other host targets. Recently, Vankadari (2020) reported the binding and
- 34 mechanism of Arbidol action over the SARS-CoV-2 spike protein, which raises the
- 35 significance of Arbidol being a possible drug candidate for COVID-19 infection.¹⁵

- 36 In this study, we aim to evaluate the clinical effect of Arbidol with a retrospective cohort of
- 37 COVID-19 patients from Wuhan. We have also conducted molecular dynamics and time
- 38 course simulation studies in order to understand the mechanism of the Arbidol drug action
- 39 over the SARS-CoV-2 viral proteins.
- 40

41 Methods

42 Study design and participants

- 43 We have assembled a cohort consisting 504 in-patients with COVID-19 from three hospitals
- 44 in Wuhan: Wuhan Pulmonary Hospital (WPH), Tongji Hospital, and Union Hospital. All three
- 45 were designated COVID-19 hospitals during the outbreak. The study protocols were reviewed
- 46 and approved by the Ethics committee of WPH (WPE 2020-12). Patient records and
- 47 information were de-identified prior to the analysis.
- 48 Figure 1 shows the diagram of cohort design and patient selection. For WPH, we started with
- 49 all COVID-19 patients admitted between December 13, 2019 and March 21, 2020 and
- 50 excluded patients with ambiguous diagnosis as well as those with a primary cause of death
- 51 unrelated to COVID-19. After further excluding 119 patients who remained being
- 52 hospitalized by March 29, 2020, 373 patients from WPH were included. For Tongji Hospital,
- 53 100 COVID-19 patients admitted into two randomly selected hospital wards between
- 54 February 1, 2020 and February 5, 2002 were included. Similarly, for Union Hospital, 31
- 55 COVID-19 patients admitted into a randomly selected ward between January 26, 2002 and
- 56 February 24, 2002 were included. All patients in the study cohort have definitive outcomes,
- 57 i.e., discharged or deceased. All COVID-19 infections are confirmed by Real-Time PCR
- 58 (virus nucleic acid test).
- 59 Patients characteristics, medication and endpoints
- 60 We collected data on patients' clinical outcomes (death or discharge) as well as basic
- 61 characteristics, including age, sex, pre-existing conditions, SpO2 level at hospital admission,
- 62 use of oxygen and ventilators during the hospital stay, and patient's pre and post treatment
- 63 lung CT scan images.
- 64 The drug treatment options used in all three hospitals followed the Chinese National Health
- 65 Commission's evolving guideline for the treatment of COVID-19, "New Corona Virus
- 66 Pneumonia Diagnosis and Treatment Program". The majority of the patients received
- 67 Lopinavir/Ritonavir, Arbidol and Oseltamivir. With the development of the epidemic and the
- 68 guideline updates, Hydroxychloroquine and Favipiravir were also used to a small number of
- 69 patients. The prescription of antiviral medications and their administration time for each
- 70 patient were extracted from electronic medical records with written consents from the

71 clinicians. In this study, we specifically focus on three anti-viral medications, Arbidol,

72 Oseltamivir, and Lopinavir/Ritonavir.

73 The primary endpoint is in-hospital death, with date of death extracted from the medical 74 records. The secondary endpoint is the change in lesion size as measured by CT scans pre and 75 post the antiviral treatment. CT scan images were read by certified thoracic radiologists at the 76 respective hospitals to determine lesion size. The pre-treatment image was selected as the first 77 CT image after the patient's admission but before the initiation of the regular full-course 78 antiviral treatment. The post-treatment image was selected as the last CT scan taken before 79 patient's death or discharge, which is normally after completing the antiviral therapy cycle. To ensure the comparability of the two CT images, we identified the plane with the largest lesion 80 in the pre-treatment CT scan, and used the same plane in the post-treatment CT scan. The 81 lesion in the selected plane was circled and size measured by the ImageJ software (Figure 2).¹⁶ 82

83 Statistical analysis

84 Continuous and dichotomous patient characteristics were summarized by their mean (standard deviation (SD)), and count (proportion), respectively. We compared the mortality rate 85 between patients who received Arbidol, or Oseltamivir, or Lopinavir/Ritonavir and those who 86 87 did not using Fisher's exact test. We then employed the logistic regression to estimate the 88 odds ratio (OR) associated with the treatment after adjusting sex, pre-existing condition, 89 medication use, hospital, and log-transformed age, SpO2 level, admission date and the lesion 90 size from the pre-treatment CT scan. Missing covariates were imputed by the medians of the 91 observed values. We also repeated the logistic regression for patients in WPH only, where the 92 potential sampling bias was the lowest. In addition, we performed Cox regression analyses with time dependent covariates, setting value to 0 and 1 before and after the medication 93 prescription, respectively, to account for the timing of medication use.¹⁷ We also conducted 94 linear regression analyses with the log-transformed ratio of lesion area absorption pre and 95 96 post the antiviral treatments. A small value of one was added to all lesions sizes to avoid log-97 transformation of zero. The two-sided statistical significance level was set at 0.05. All 98 statistical analyses were conducted using the R 3.3.1 software.

99 Arbidol binding analysis

100 Docking studies with Arbidol and its binding analysis to SARS-CoV-2 spike glycoprotein was

- 101 performed as described in Vankadari (2020).¹⁵ In brief, SwissDock
- 102 (http://swissdock.ch/docking) server was used to dock the Arbidol into the published structure
- 103 of SARS-CoV-2 spike glycoprotein trimer (PDB: 6VSB). Structural refinement was
- 104 completed using Coot (www.mrc-imb.cam.uk/) to ensure no clashes in the side chain
- 105 residues. Best dock score and highest binding free energies were taken into consideration to
- 106 select the best-possible docking site and mode of interaction. Arbidol binding interface and

3

- 107 the key residues interaction map was generated using the Maestro program. The molecular
- 108 dynamics with time course simulation studies were performed using DynOmics server (www.
- 109 http://gnm.csb.pitt.edu/). The final model with Arbidol docked in the homotrimer structure of
- 110 SARS-CoV-2 spike protein and all other structural figures were visualized using PyMol.
- 111 Role of the funding source
- 112 The authors report no funding.

113

114 **Results**

115 Cohort baseline characteristics

- 116 The cohort consists of 504 patients with confirmed COVID-19 infection from three hospitals:
- 117 373 patients from WPH, 100 patients from the Tongji Hospital, and 31 patients from the
- 118 Union hospital. Table 1 summarizes main drug treatment options administrated during
- patient's stay at the respective hospital. 257 patients received Arbidol (51.0%); 66 patients
- received Oseltamivir (13.1%); and 259 patients received Lopinavir/Ritonavir (51.4%). The
- 121 majority of the patients received two or more different treatments during their hospitalization.
- Among the 504 patients, 245 (48.6%) were female, and 262 (52.0%) had pre-existing
- 123 conditions. The average age of the cohort was 59.5 (SD, 14.9) years old. The average Oxygen
- 124 level (SpO2) at admission was 92.8% (9.3%). Patients who received Arbidol had slightly
- 125 higher SpO2 level and smaller lesion area compared to other patients. Patients who received
- 126 Oseltamivir were younger. In contrast, patients who received Lopinavir/Ritonavir had more
- 127 pre-existing conditions. Patients admitted to the hospital early were more likely to receive
- 128 Oseltamivir and Lopinavir/Ritonavir. Table 2 summarizes the baseline patients characteristics129 by hospital.
- 130 The association between the treatments and mortality
- For the cohort of 504 patients, the overall mortality rate was 15.67%. The mortality rate was 9.39% among females, 21.62% among males. The mortality rate was 20.23% among patients with pre-existing conditions, and 10.74% among patients without pre-existing conditions. The mortality rate was 17.96% in WPH, 12.00% in Tongji Hospital, and 0% in Union hospital. In this cohort, older age, lower SpO2 level at admission, larger lesion, and early admission date were associated with higher mortality.
- 137 The mortality rate was 7.00% among patients who received Arbidol compared to 24.70%
- 138 among patients who did not. The odds ratio (OR) was 0.230 (95% confidence interval (CI),
- 139 0.124 to 0.411) favoring Arbidol. On the other hand, the mortality rate was 12.12% among
- 140 patients who received Oseltamivir, compared to 16.21% among patients who did not. The OR

141 was 0.713 (95% CI, 0.282 to 1.589) favoring Oseltamivir. The mortality rate was 14.29%

- 142 among patients who received Lopinavir/Ritonavir, compared to 17.14% among patients who
- 143 did not. The OR was 0.806 (95% CI, 0.483 to 1.341) favoring Lopinavir/Ritonavir. After
- 144 adjusting for sex, pre-existing conditions, log(age), log(SpO2), log(lesion size), log(admission
- 145 date) and hospital (model 1) using a multivariate logistic regression model, the OR was 0.169
- 146 (95% CI, 0.071 to 0.398) for Arbidol, 0.212 (95% CI, 0.072 to 0.623) for Oseltamivir, and
- 147 0.363 (95% CI, 0.165 to 0.795) for Lopinavir/Ritonavir. After further adjustment of
- 148 concurrent antiviral medications (model 2), the beneficial effect of Arbidol and Oseltamivir
- have remained statistically significant: the adjusted OR was 0.183 (95% CI, 0.075 to 0.446;
- 150 p<0.001) for Arbidol and 0.220 (95% CI, 0.069 to 0.707; P=0.011) for Oseltamivir (Figure
- 151 3A).

152 The association between the treatments and the reduction of lung lesion sizes

153 There were 326 survivors with two available CT scans. The average reductions in lesion size 154 were 46.43% (SD: 29.00%) among the 209 patients who received Arbidol and 36.80% (SD: 155 24.95%) among the 117 patients who did not. The average reduction among the 55 patients 156 who received Oseltamivir was less than that among the 271 patients who did not (41.18% vs 157 43.34%). The reduction among the 186 patients who received Lopinavir/Ritonavir was also less than the 140 patients who did not (37.26% vs. 50.56%). After adjusting for patients' 158 159 characteristics and concurrent antiviral drug use using a multivariate linear regression model, 160 the ratio of the lesion size (post-treatment to pre-treatment) among patients who received 161 Arbidol was 85.20% (95% CI, 74.47% to 97.48%; P=0.0203) of that among patients who did 162 not, suggesting a faster lesion absorption. Figure 3B summarized the linear regression 163 analysis results for all three antiviral drugs. Figure 4A shows the boxplots of the lesion 164 absorptions in the stratified subgroups of patients by the three antiviral drugs, with patients 165 who received Arbidol (dark turquoise) showing more absorption than patients who did not 166 (light turquoise).

167 Subgroup analysis in WPH

- 168 For the 373 patients in WPH, the mortality rate was 7.09% among patients who received
- 169 Arbidol vs. 24.57% among patients who did not (OR=0.234, 95% CI, 0.103 to 0.481,
- 170 P<0.001). After adjusting for sex, pre-existing condition, log(age), log(SpO2), log(lesion
- area), log(admission date), and concurrent antiviral drug use using a multivariate logistic
- regression model, Arbidol was associated with significantly reduced mortality (OR, 0.193;
- 173 95% CI, 0.071 to 0.520, P=0.001). The effect of Oseltamivir was marginally significant (OR,
- 174 0.326; 95% CI, 0.090 to 1.177; P=0.087). Figure 3C summarized detailed results.

175 Survival analysis

176 Among the patients who received Arbidol, the median prescription time was 1.50 (IQR: 0.50-

- 177 2.50, range, 0.50-31.50) days after admission. For Oseltamivir and Lopinavir/Ritonavir, the
- median prescription time was 0.50 (IQR: 0.50 to 1.50, range, 0.50-25.50) and 0.50 (IQR:
- 179 0.50 to 2.50, range, 0.50-32.50) days after admission, respectively. After adjusting for
- 180 baseline characteristics and concurrent antiviral drug use using a multivariate cox
- 181 proportional hazard ratio model, the hazard ratio was 0.350 (95% CI, 0.177 to 0.689;
- 182 P=0.002) for Arbidol, 0.571 (95% CI, 0.269 to 1.211) for Oseltamivir, and 0.720 (95% CI,
- 183 0.426 to 1.218) for Lopinavir/Ritonavir based on Cox regression stratified by hospitals
- 184 (Figure 3D). Figure 4B shows the cumulative mortality curves for the three antiviral drugs.
- 185 There is a significant difference between the mortality curve for patients who received
- 186 Arbidol versus patients who did not (P < 0.001) whereas the differences are not statistically
- 187 significant for Oseltamivir (P = 0.34) and Lopinavir/Ritonavir (P = 0.33).

188 Arbidol and SARS-CoV-2 spike glycoprotein interaction

189 It is evident from the previous studies that Arbidol is potentially effective against SARS-CoV-2.13 The recent structural studies of Arbidol in complex with SARS-CoV-2 spike 190 glycoprotein underlines its role in impeding trimerization,¹⁵ which is essential for virulence. 191 192 Here we address how this drug disrupts the viral spike glycoprotein through comprehensive 193 drug interaction via molecular dynamics and time course simulation studies. As shown in 194 Figure 5A, each monomer of spike glycoprotein consists of large surface for drug interaction 195 and it could completely accommodate the drug in the trimer interface (Figure 5A and 5B). 196 The time course simulation and drug interaction studies show that the Arbidol disrupt the 197 interface in all directions and its binding affinity found to be very high (Figure 5C). The 198 interaction is not only mediated by hydrogen bonding and van-der Wall forces but also by 199 several polar residues bridge with the spike glycoproteins (Figure 5D). Furthermore, the 200 dynamic simulation and domain movement or oscillation studies show that binding of Arbidol 201 to the spike glycoprotein increases the B-factor (stability factor) (Figure 5E), suggesting 202 protein is under higher movement and is less stable or tend to dissociate from other 203 monomers. These structural and molecular dynamic studies further corroborate our clinical 204 finding of CT scans showing greater viral clearance observed with Arbidol treatment.

205

206 Discussion

- 207 The study showed promising treatment effect of Arbidol on mortality and lesion absorption.
- 208 On the other hand, the benefit of Lopinavir/Ritonavir is inconclusive, which is consistent with
- 209 the previous finding of Cao et al. (2020), where Lopinavir/Ritonavir has reduced the mortality
- from 25.0% to 19.2% in a randomized clinical trial, but failed to reach the statistical
- significance threshold.⁸ Recently, Xu et al, (2020) reported that the virologic conversion rate

212 in 49 patients who received Arbidol was significantly higher than that in 62 patients who received the standard care (59.2% vs 40.3%, P=0.048).¹⁹ In this study, the patients who 213 214 received Arbidol also had faster lung lesion absorption (55.1% vs 32.2%). Despite the limited 215 sample size, their results further corroborated our findings. The dual role of Arbidol in 216 inhibiting the fusion between the viral envelope and target host cell membrane as well as antiinflammation could be responsible for its observed efficacy.^{20, 21} 217 218 Oseltamivir is normally prescribed for the treatment of influenza and has no known effect on 219 COVID-19 patients. However, some patients have been infected by both COVID-19 and Influenza,²² which may exacerbate their clinical conditions. It is very likely that a 220 221 combination of drugs or therapy including Oseltamivir can help this subgroup of patients due 222 to the effectiveness of Oseltamivir in treating severe illness caused by Influenza. In addition, 223 SARS-CoV-2 and influenza viruses share a similar region of viral spike protein, which may 224 also explain the potential effect of Oseltamivir in treating COVID-19 patients.¹³ 225 There are some important limitations in the current study. First, the study is not a randomized 226 clinical trial, and therefore the observed treatment benefit of Arbidol and Oseltamivir may be 227 due to confounding effect. The analysis has adjusted for several known confounders including 228 age, comorbidities, admission date, and disease severity measured through SpO2 and CT 229 scan. Furthermore, given the size of the estimated treatment effect, the unmeasured 230 confounding effect needs to be very strong to completely account for this benefit. Second, we 231 didn't account for the effect of important supporting treatment such as oxygen and ventilator 232 use. Their availability and deployment may affect the estimated treatment effect. Third, 233 although the cohort size is 504, the patients from Tongji and Union Hospitals are not 234 necessarily the most representative samples of patients admitted into these hospitals. For 235 example, ICU patients in these two hospitals are not included. We have also excluded 236 surviving patients not yet discharged from WPH by March 29, 2020, and consequently, the 237 observed mortality rate among patients from WPH is substantially higher than that from 238 Tongji and Union Hospitals. These sampling biases may affect the interpretation and 239 generalizability of our findings. For example, the reported mortality rate doesn't represent the 240 absolute mortality rate in the patients admitted into relevant hospital. Furthermore, there are 241 only 33 patients who received both Arbidol and Oseltamivir in the entire cohort, which limits 242 the reliability of the estimated treatment benefit associated with the combination therapy. On the other hand, despite the limited sample size and selective sampling, all identified risk 243 factors in the current study are consistent with other studies,^{22,23} which indirectly supports our 244 245 findings on the treatment efficacy. The association between admission date and mortality can 246 also be explained by the availability of medical resources. Lastly, regarding the adverse 247 events, nausea was observed in a small group of patients who received Arbidol. Loss of 248 appetite was observed in patients who received Oseltamivir. Whereas Diarrhea, nausea, 249 vomiting, loss of appetite and decreased sleep quality were observed in patients who received 250 Lopinavir/Ritonavir. Due to the difficulty in accurate and complete documentation of all

- adverse events during the pandemic, the study team did not summarize these data in this
- 252 report. Nevertheless, it is known that the severe adverse effects associated with the use of
- 253 Arbidol and Oseltamivir have been very rare.^{21,24}
- Arbidol is originated from Russia as a broad-spectrum antiviral drug and is now widely used
- 255 in Russia as an OTC drug and in China as a prescription drug. Although Arbidol was reported
- to effectively shorten the duration of influenza and prevent the development of post-influenza
- 257 complications, reduce the re-infection risk based on multiple clinical trials conducted in
- 258 Russia and China,²⁵ due to lack of detailed information regarding these trials, WHO suggested
- that the results should be interpreted with caution.²⁶ Consequently, Arbidol has not received
- 260 FDA approval in the United States and the use of Arbidol in other parts of the world has been
- 261 limited. However, while drafting this manuscript, we have found that eight clinical trials
- 262 (NCT04350684, NCT04286503, NCT04260594, NCT04273763, NCT04323345,
- 263 NCT04261907, NCT04306497, NCT04333589) in China, Iran and Egypt involving Arbidol
- in treating COVID-19 patients were registered at www.clinicaltrial.gov.
- 265 In conclusion, our clinical and molecular biological findings suggest that Arbidol might be a
- 266 potentially effective treatment for COVID-19. Further clinical studies including RCTs are
- 267 warranted for statistical and clinical evaluation of its efficacy.

268

269 References 270 1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases 271 of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020 272 Feb 15;395(10223):507-513. doi: https://doi.org/10.1016/S0140-6736(20)30211-7. Epub 273 2020 Jan 30. 274 2. WHO Coronavirus disease (COVID-2019) situation reports. 275 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports 276 (accessed May 22,2020) 277 3. Xie M, Chen O. Insight into 2019 novel coronavirus - an updated interim review and 278 lessons from SARS-CoV and MERS-CoV. Int J Infect Dis. 2020 Apr 1. pii: S1201-279 9712(20)30204-6. doi: https://doi.org/10.1016/j.ijid.2020.03.071. [Epub ahead of print] 280 4. Vanden EJ. COVID-19: A Brief Overview of the Discovery Clinical Trial. 281 Pharmaceuticals (Basel) 2020 Apr 10;13(4):E65. doi: 282 https://doi.org/10.3390/ph13040065. 283 5. Liu S, Lin H, Baine I, et al. Convalescent plasma treatment of severe COVID-19: A 284 matched control study. medRxiv preprint doi: 285 https://doi.org/10.1101/2020.05.20.20102236. 286 6. Mehra MR, Desai SS, Frank R, et al. Hydroxychloroquine or chloroquine with or without 287 a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet. 288 2020 May 22. doi: https://doi.org/10.1016/S0140-6736(20)31180-6 289 7. Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in 290 Hospitalized Patients with Covid-19. N Engl J Med. 2020 May 7. doi: 291 https://doi.org/10.1056/NEJMoa2012410 292 8. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with 293 Severe Covid-19. N Engl J Med. 2020 Mar 18. doi: 294 https://doi.org/10.1056/NEJMoa2001282. [Epub ahead of print] 295 9. Chen C, Zhang Y, Huang J, et al. Favipiravir versus Arbidol for COVID-19: A 296 Randomized Clinical Trial. medRxiv preprint doi: 297 https://doi.org/10.1101/2020.03.17.20037432. 298 10. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A. Compassionate Use of 299 Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020 April 10, at 300 NEJM.org. doi: https://doi.org/10.1056/NEJMoa2007016 301 11. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 — 302 Preliminary Report. N Engl J Med. 2020 May 22, doi:

303	https://doi.org/10.1056/NEJMoa2007764
304	 Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y. Remdesivir in Adults With Severe COVID-
305	19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial. Lancet. 2020
306	May 16;395(10236):1569–1578. doi: https://doi.org/10.1016/S0140-6736(20)31022-9.
307	Epub 2020 Apr 29.
308	 Vankadari N, Wilce JA. Emerging COVID-19 coronavirus: glycan shield and structure
309	prediction of spike glycoprotein and its interaction with human CD26. Emerging
310	Microbes & Infections 9:1, pages 601–604. 2020
311	14. Li, Y, Zhang, Z, Yang, L, et al. The MERS-CoV receptor DPP4 as a candidate binding
312	target of the SARS-CoV-2 spike, ISCIENCE (2020), doi:
313	https://doi.org/10.1016/j.isci.2020.101160.
314	15. Vankadari N. Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by
315	blocking the trimerization of viral spike glycoprotein? International Journal of
316	Antimicrobial Agents 105998 (2020) doi:
317	https://doi.org/10.1016/j.ijantimicag.2020.105998.
318 319	16. Image manipulation and analysis software: ImageJ freeware obtained from http://imagej.nih.gov/ij/.
320	 Xu R, Luo Y. Chambers C. 2012. Assessing the effect of vaccine on spontaneous abortion
321	using time- dependent covariates Cox models. Pharmacoepidemiology and drug
322	safety, 21(8), pp.844–850.
323	 Wang X, Cao R, Zhang H, et al. The anti-influenza virus drug, arbidol is an efficient
324	inhibitor of SARS-CoV-2 in vitro. Cell Discov 6, 28 (2020).
325	https://doi.org/10.1038/s41421-020-0169-8
326	 Xu K, Chen Y, Yuan J, Yi P, Ding C, Wu W. Clinical Efficacy of Arbidol in Patients with
327	2019 Novel Coronavirus-Infected Pneumonia: A Retrospective Cohort Study (2020 Feb
328	12). Available at http://dx.doi.org/10.2139/ssrn.3542148
329	 Proskurnina E, Izmailov D, Sozarukova M, Zhuravleva T, Leneva I, Poromov A.
330	Antioxidant Potential of Antiviral Drug Umifenovir. Molecules. 2020 Mar 30;25(7). pii:
331	E1577. doi: https://doi.org/10.3390/molecules25071577.
332	 Blaising J, Polyak SJ, Pécheur EI. Arbidol as a broad-spectrum antiviral: An
333	update. Antiviral Res. 2014;107(1):84–94. doi:
334	https://doi.org/10.1016/j.antiviral.2014.04.006.
335 336	22. Ding Q, Lu P, Fan Y, Xia Y, Liu M. The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus

337	in Wuhan, China. J Med Virol. 2020 Mar 20. doi: https://doi.org/10.1002/jmv.25781.
338	[Epub ahead of print]
339 340 341 342	23. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054–1062. doi: https://doi.org/10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
343	24. Uyeki T. Oseltamivir Treatment of Influenza in Children. Clin Infect
344	Dis. 2018;66(10):1501–1503.
345 346	25. Boriskin YS, Leneva IA, Pecheur EI, Polyak SJ. Arbidol: a broad- spectrum antiviral compound that blocks viral fusion. Curr Med Chem 2008;15(10):997–1005.
347	26. Who. WHO Guidelines for Pharmacological Management of Pandemic Influenza
348	A(H1N1) 2009 and other Influenza Viruses. WHO Guidel. Pharmacol. Manag. Pandemic
349	Influ. A(H1N1) 2009 other Influ. Viruses 1–32 (2010)
350 351	

353	
	Table 1. Administered treatments for patients in three hospitals
354	

	WPH n=373	Tongji n=100	Union n=31	Total n=504
Arbidol	141 (37.8%)	94 (94.0%)	22 (71.0%)	257 (51.0%)
Oseltamivir	46 (12.3%)	19 (19.0%)	1 (3.2%)	66 (13.1%)
Lopinavir/Ritonavir	245 (65.7%)	4 (4.0%)	10 (32.3%)	259 (51.4%)
Chloroquine	4 (1.1%)	0 (0.0%)	0 (0.0%)	4 (0.8%)
Hydroxycholoroquine	3 (0.8%)	0 (0.0%)	0 (0.0%)	3 (0.6%)
Favipiravir	4 (1.1%)	0 (0.0%)	0 (0.0%)	4 (0.8%)
Ganciclovir	28 (7.5%)	0 (0.0%)	2 (6.5%)	30 (6.0%)
Glucocorticoid	151 (40.5%)	73 (73.0%)	6 (19.4%)	230 (45.6%)
Immunoglobin	117 (31.4%)	25 (25.0%)	10 (32.3%)	152 (30.2%)
Albumin	71 (19.0%)	15 (15.0%)	2 (6.5%)	88 (17.5%)
Oxygen	318 (85.3%)	86 (86.0%)	23 (74.2%)	427 (84.7%)
Ventilation	43 (11.5%)	12 (12.0%)	0 (0%)	55 (10.9%)

358 Table 2. Distributions of Baseline Characteristics by Medication and Hospital

359

	WPH		Tongji		Union		Total		
		Arbido				1			
	Yes	No	Yes	No	Yes	No	Yes	No	
	n=141	n=232	n=94	n=6	n=22	n=9	n=257	n=247	
Age (year)	$61.3 (14.2)^{(1)}$	60.3 (15.0)	55.8 (14.6)	68.5 (9.6)	58.2 (17.3)	46.4 (15.3)	59.1 (14.8)	60.0 (15.1)	
Female	72	112	41	3	12	5	125	120	
	(51.1%)	(48.3%)	(43.6%)	(50.0%)	(54.5%)	(55.6%)	(48.6%)	(48.6%)	
Pre-existing conditions	90	119	33	5	11	4	134	128	
	(63.8%)	(51.3%)	(3 5.1%)	(83.3%)	(50.0%)	(44.4%)	(52.1%)	(51.8%)	
SpO2 level	93.6	91.7	93.9	81.3	95.8	96.8	93.9	91.6	
(%)	(4.3)	(12.2)	(6.4)	(14.9)	(1.4)	(1.1)	(5.0)	(12.1)	
Lesion Size (cm ²)	56.1	65.5	46.8	44.6	55.4	50.8	52.7	64.6	
	(43.4)	(48.4)	(31.2)	(19.7)	(38.9)	(42.6)	(39.1)	(47.9)	
Admission	65.0	61.2	52.8	52.5	55.5	55.4	59.7	60.8	
Date ⁽²⁾ (day)	(13.4)	(22.0)	(1.4)	(1.4)	(7.3)	(5.5)	(11.7)	(21.4)	
				Oseltami	vir		••		
	Yes	No	Yes	No	Yes	No	Yes	No	
	n=46	n=327	n=19	n=81	n=1	n=30	n=66	n=438	
Age	59.1	60.9	52.1	57.7	66.0	54.4	57.2	59.9	
(year)	(13.5)	(14.8)	(12.8)	(14.9)		(17.5)	(13.6)	(15.1)	
Female	24	160	9	35	1	16	34	211	
	(52.2%)	(48.9%)	(47.4%)	(43.2%)	(100%)	(53.3%)	(51.5%)	(48.2%)	
Pre-existing	27	182	4	34	1	14	32	230	
Conditions	(58.7%)	(55.7%)	(21.1%)	(42.0%)	(100%)	(46.7%)	(48.5%)	(52.5%)	
SpO2 level	92.8	92.4	92.6	93.3	94.0	96.2	92.8	92.8	
(%)	(6.4)	(10.4)	(7.7)	(7.7)		(1.3)	(6.7)	(9.6)	
Lesion Size	67.8	60.3	47.1	46.7	43.0	54.5	61.5	57.2	
(cm ²)	(46.1)	(46.5)	(39.5)	(28.5)		(39.8)	(44.6)	(43.4)	
Admission	42.2	65.5	53.2	52.6	63.0	55.2	45.7	62.4	
Date (day)	(10.1)	(18.5)	(1.2)	(1.4)		(6.7)	(10.0)	(16.9)	
			L	opinavir/Ri	tonavir				
	Yes	No	Yes	No	Yes	No	Yes	No	
	n=245	n=128	n=4	n=96	n=10	n=21	n=259	N=245	
Age	60.3	61.4	39.2	57.3	53.5	55.4	59.7	59.3	
(year)	(13.4)	(16.9)	(16.3)	(14.2)	(12.4)	(19.5)	(13.6)	(16.2)	
Female	122	62	2	42	6	11	130	115	
	(49.8%)	(48.4%)	(50.0%)	(43.8%)	(60.0%)	(52.4%)	(50.2%)	(46.9%)	
Pre-existing	145	64	1	37	5	10	151	111	
Conditions	(59.2%)	(50.0%)	(25.0%)	(38.5%)	(50.0%)	(47.6%)	(58.3%)	(45.3%)	
SpO2 level	92.5	92.2	95.0	93.1	96.9	95.7	92.7	92.9	
(%)	(8.5)	(12.4)	(4.1)	(7.8)	(0.9)	(1.4)	(8.3)	(10.2)	
Lesion Size	61.6	61.0	22.6	48.0	44.4	59.0	60.2	55.1	
(cm ²)	(47.2)	(44.9)	(17.3)	(31.0)	(30.8)	(42.6)	(46.6)	(39.5)	
Admission	58.1	71.4	53.0	52.7	52.8	56.7	57.8	62.8	
Date (day)	(15.4)	(22.7)	(1.6)	(1.4)	(5.0)	(7.2)	(15.0)	(18.8)	

360

361



Figure 1: Diagram of cohort design and patient selection



Figure 2: Chest CT scan images before and after the antiviral treatment. The shaded areas circled by the yellow line were the lesion areas. Using ImageJ, we were able to quantify the sizes of the lesions in terms of squared centimeters. (**A**) A male patient in his 50s with no underlying diseases who have received Arbidol alone. (**B**) A male patient in his 50s with no underlying diseases who have received Oseltamivir + Lopinavir/Ritonavir, since no patient has received Oseltamivir alone. (**C**) A male patient in his 50s with no underlying diseases who have received.



Figure 3: (A) The estimated OR and associated 95% CI for Arbidol, Oseltamivir and Lopinavir/Ritonavir. (B) The estimated effect on relative change in lesion size and associated 95% CI for Arbidol, Oseltamivir and Lopinavir/Ritonavir. An effect less than 1 suggests that more relative reduction in lesion size is associated with the medicine of interest. (C) The estimated OR and associated 95% CI for Arbidol, Oseltamivir and Lopinavir/Ritonavir and Lopinavir/Ritonavir among 373 patients from WPH. (D) The estimated hazard ratio and associated 95% CI for Arbidol, Oseltamivir and Lopinavir/Ritonavir based on the Cox regression analyses with time dependent covariates accounting for timings of medication use.

Model 1: adjusting for sex, pre-existing condition, log(age), log(SpO2), hospital, log(lesion size) and log(admission date); Model 2: adjusting for confounders in Model 1 and medication use (Arbidol, Oseltamivir, and Lopinavir/Ritonavir).



Figure 4: (A) Boxplot of the lesion absorption rate before and after the antiviral treatment, as shown in chest CT scan, compared among Arbidol, Oseltamivir, and Lopinavir/Ritonavir groups. In these boxplots we included CT lesion measures from all patients (deceased and discharged). (B) Cumulative mortality rate curves by medication use (Arbidol, Oseltamivir, and Lopinavir/Ritonavir). P-value of the log-rank tests are displayed and the shaded area shows the 95% confidence intervals



Figure 5: Surface and ribbon model showing the full length monomer (**A**) and homo-trimer (**B**) structure of SARS-CoV-2 spike glycoprotein. Position of S1 and S2 domains are labelled and bound Arbidol with high affinity at the center is shown in sticks. Each monomer of homo-trimer is shown in different colour.

Table 1. Administered treatments for patients in three hospitals

	WPH n=373	Tongji n=100	Union n=31	Total n=504
Arbidol	141 (37.8%)	94 (94.0%)	22 (71.0%)	257 (51.0%)
Oseltamivir	46 (12.3%)	19 (19.0%)	1 (3.2%)	66 (13.1%)
Lopinavir/Ritonavir	245 (65.7%)	4 (4.0%)	10 (32.3%)	259 (51.4%)
Chloroquine	4 (1.1%)	0 (0.0%)	0 (0.0%)	4 (0.8%)
Hydroxycholoroquine	3 (0.8%)	0 (0.0%)	0 (0.0%)	3 (0.6%)
Favipiravir	4 (1.1%)	0 (0.0%)	0 (0.0%)	4 (0.8%)
Ganciclovir	28 (7.5%)	0 (0.0%)	2 (6.5%)	30 (6.0%)
Glucocorticoid	151 (40.5%)	73 (73.0%)	6 (19.4%)	230 (45.6%)
Immunoglobin	117 (31.4%)	25 (25.0%)	10 (32.3%)	152 (30.2%)
Albumin	71 (19.0%)	15 (15.0%)	2 (6.5%)	88 (17.5%)
Oxygen	318 (85.3%)	86 (86.0%)	23 (74.2%)	427 (84.7%)
Ventilation	43 (11.5%)	12 (12.0%)	0 (0%)	55 (10.9%)

	WPH		Tongji		Union		Total	
			Arbidol					
	Yes	No	Yes	No	Yes	No	Yes	No
	n=141	n=232	n=94	n=6	n=22	n=9	n=257	n=247
Age	61.3	60.3	55.8	68.5	58.2	46.4 (15.3)	59.1	60.0
(year)	(14.2) ⁽¹⁾	(15.0)	(14.6)	(9.6)	(17.3)		(14.8)	(15.1)
Female	72	112	41	3	12	5	125	120
	(51.1%)	(48.3%)	(43.6%)	(50.0%)	(54.5%)	(55.6%)	(48.6%)	(48.6%)
Pre-existing conditions	90	119	33	5	11	4	134	128
	(63.8%)	(51.3%)	(3 5.1%)	(83.3%)	(50.0%)	(44.4%)	(52.1%)	(51.8%)
SpO2 level	93.6	91.7	93.9	81.3	95.8	96.8	93.9	91.6
(%)	(4.3)	(12.2)	(6.4)	(14.9)	(1.4)	(1.1)	(5.0)	(12.1)
Lesion Size (cm ²)	56.1	65.5	46.8	44.6	55.4	50.8	52.7	64.6
	(43.4)	(48.4)	(31.2)	(19.7)	(38.9)	(42.6)	(39.1)	(47.9)
Admission	65.0	61.2	52.8	52.5	55.5	55.4	59.7	60.8
Date ⁽²⁾ (day)	(13.4)	(22.0)	(1.4)	(1.4)	(7.3)	(5.5)	(11.7)	(21.4)
			-	Oseltami	vir			
	Yes	No	Yes	No	Yes	No	Yes	No
	n=46	n=327	n=19	n=81	n=1	n=30	n=66	n=438
Age	59.1	60.9	52.1	57.7	66.0	54.4	57.2	59.9
(year)	(13.5)	(14.8)	(12.8)	(14.9)		(17.5)	(13.6)	(15.1)
Female	24	160	9	35	1	16	34	211
	(52.2%)	(48.9%)	(47.4%)	(43.2%)	(100%)	(53.3%)	(51.5%)	(48.2%)
Pre-existing	27	182	4	34	1	14	32	230
Conditions	(58.7%)	(55.7%)	(21.1%)	(42.0%)	(100%)	(46.7%)	(48.5%)	(52.5%)
SpO2 level	92.8	92.4	92.6	93.3	94.0	96.2	92.8	92.8
(%)	(6.4)	(10.4)	(7.7)	(7.7)		(1.3)	(6.7)	(9.6)
Lesion Size	67.8	60.3	47.1	46.7	43.0	54.5	61.5	57.2
(cm ²)	(46.1)	(46.5)	(39.5)	(28.5)		(39.8)	(44.6)	(43.4)
Admission	42.2	65.5	53.2	52.6	63.0	55.2	45.7	62.4
Date (day)	(10.1)	(18.5)	(1.2)	(1.4)		(6.7)	(10.0)	(16.9)
			L	opinavir/Ri	tonavir			
	Yes	No	Yes	No	Yes	No	Yes	No
	n=245	n=128	n=4	n=96	n=10	n=21	n=259	N=245
Age	60.3	61.4	39.2	57.3	53.5	55.4	59.7	59.3
(year)	(13.4)	(16.9)	(16.3)	(14.2)	(12.4)	(19.5)	(13.6)	(16.2)
Female	122	62	2	42	6	11	130	115
	(49.8%)	(48.4%)	(50.0%)	(43.8%)	(60.0%)	(52.4%)	(50.2%)	(46.9%)
Pre-existing	145	64	1	37	5	10	151	111
Conditions	(59.2%)	(50.0%)	(25.0%)	(38.5%)	(50.0%)	(47.6%)	(58.3%)	(45.3%)
SpO2 level	92.5	92.2	95.0	93.1	96.9	95.7	92.7	92.9
(%)	(8.5)	(12.4)	(4.1)	(7.8)	(0.9)	(1.4)	(8.3)	(10.2)
Lesion Size	61.6	61.0	22.6	48.0	44.4	59.0	60.2	55.1
(cm ²)	(47.2)	(44.9)	(17.3)	(31.0)	(30.8)	(42.6)	(46.6)	(39.5)
Admission	58.1	71.4	53.0	52.7	52.8	56.7	57.8	62.8
Date (day)	(15.4)	(22.7)	(1.6)	(1.4)	(5.0)	(7.2)	(15.0)	(18.8)

Table 2. Distributions of Baseline Characteristics by Medication and Hospital



Figure 1: Diagram of cohort design and patient selection



Figure 2: Chest CT scan images before and after the antiviral treatment. The shaded areas circled by the yellow line were the lesion areas. Using ImageJ, we were able to quantify the sizes of the lesions in terms of squared centimeters. (**A**) A male patient in his 50s with no underlying diseases who have received Arbidol alone. (**B**) A male patient in his 50s with no underlying diseases who have received Oseltamivir + Lopinavir/Ritonavir, since no patient has received Oseltamivir alone. (**C**) A male patient in his 50s with no underlying diseases who have received Lopinavir/Ritonavir alone.



Figure 3: (**A**) The estimated OR and associated 95% CI for Arbidol, Oseltamivir and Lopinavir/Ritonavir. (**B**) The estimated effect on relative change in lesion size and associated 95% CI for Arbidol, Oseltamivir and Lopinavir/Ritonavir. An effect less than 1 suggests that more relative reduction in lesion size is associated with the medicine of interest. (**C**) The estimated OR and associated 95% CI for Arbidol, Oseltamivir and Lopinavir/Ritonavir among 373 patients from WPH. (**D**) The estimated hazard ratio and associated 95% CI for Arbidol, Oseltamivir and Lopinavir/Ritonavir among 373 patients from WPH. (**D**) The estimated hazard ratio and associated 95% CI for Arbidol, Oseltamivir and Lopinavir/Ritonavir based on the Cox regression analyses with time dependent covariates accounting for timings of medication use.

Model 1: adjusting for sex, pre-existing condition, log(age), log(SpO2), hospital, log(lesion size) and log(admission date); Model 2: adjusting for confounders in Model 1 and medication use (Arbidol, Oseltamivir, and Lopinavir/Ritonavir).



Figure 4: (**A**) Boxplot of the lesion absorption rate before and after the antiviral treatment, as shown in chest CT scan, compared among Arbidol, Oseltamivir, and Lopinavir/Ritonavir groups. In these boxplots we included CT lesion measures from all patients (deceased and discharged). (**B**) Cumulative mortality rate curves by medication use (Arbidol, Oseltamivir, and Lopinavir/Ritonavir). P-value of the log-rank tests are displayed and the shaded area shows the 95% confidence intervals



Figure 5: Surface and ribbon model showing the full length monomer (**A**) and homo-trimer (**B**) structure of SARS-CoV-2 spike glycoprotein. Position of S1 and S2 domains are labelled and bound Arbidol with high affinity at the center is shown in sticks. Each monomer of homo-trimer is shown in different colour